Novartis India Ltd

Evonile Pharma Limited, formerly known as Novartis India Limited, announced the designation of Mr. Gagan Sharma, President Specialty Business, as a Senior Management Personnel, effective October 26, 2026.

Evonile Pharma Limited, formerly known as Novartis India Limited, announced that its board approved a rights issue to raise up to Rs 9,000 million through the issuance of partly paid-up equity shares to eligible shareholders, subject to regulatory approvals. The company also formed a Rights Issue Committee consisting of Mr. Vikas Gupta, Dr. Jagriti Gupta, and Mr. Shashank Sinha to finalize the terms and conditions of the rights issue, and approved the adoption and launch of a new corporate website at www.evonilepharma.com.

Evonile Pharma Limited (formerly Novartis India Limited) plans to raise up to Rs 9,000 million through a rights issue of partly paid-up equity shares with a face value of Rs 5 each, to be offered to eligible shareholders on a record date to be determined later, subject to statutory and regulatory approvals. The company has constituted a Rights Issue Committee to finalize the issue details, including the rights entitlement ratio and issue price, and the total number of securities to be issued will be determined at a later date. The board also approved a postal ballot notice for shareholder approval and the launch of a new corporate website at www.evonilepharma.com.

Novartis India Ltd, now operating as Evonile Pharma Limited, announced on October 7, 2026, that CARE Ratings Limited has assigned credit ratings to the company's bank facilities; specifically, CARE Ratings Limited assigned a CARE A rating to the Long Term Bank Facilities, a CARE A; Stable rating to the Long Term / Short Term Bank Facilities, and a CARE A2+ rating to the Long Term / Short Term Bank Facilities. The rating rationale issued by CARE Ratings Limited is available on its website and also on the company’s website at www.nilpharma.co.in, and this disclosure is made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Evonile Pharma Limited, formerly known as Novartis India Limited, will seek to raise funds through a rights issue of equity shares with a face value of Rs 5 each to its eligible shareholders, according to a regulatory filing with the BSE Limited on October 05, 2026. The company’s Board of Directors is scheduled to meet on October 08, 2026, to consider the terms and conditions of the proposed fund-raising, which is subject to regulatory approvals. Trading window for company insiders has been closed from October 01, 2026, until November 05, 2026.

Novartis India Limited will hold a board meeting on Tuesday, November 03, 2026, to consider and approve the unaudited financial results for the quarter and half year ended September 30, 2026, according to a regulatory filing with the BSE Limited. The trading window for the company's designated persons will be closed from October 01, 2026, and will reopen 48 hours after the financial results are declared.

Novartis India Limited will hold a board meeting on Tuesday, November 03, 2026, to consider and approve the unaudited financial results for the quarter and half year ended September 30, 2026, according to a regulatory filing with the BSE Limited. The trading window for the company's designated persons will be closed from October 01, 2026, and will reopen 48 hours after the financial results are declared.

Bal Pharma Ltd, Anmol India Ltd, Medi Caps Ltd and Goa Carbon Ltd are among the other gainers in the BSE's 'B' group today, 09 September 2026.Novartis India Ltd surged 20.00% to Rs 2188 at 12:03 IST. The stock was the biggest gainer in the BSE's 'B' group. On the BSE, 53989 shares were traded on the counter so far as against the average daily volumes of 10661 shares in the past one month. Bal Pharma Ltd spiked 20.00% to Rs 114.02. The stock was the second biggest gainer in 'B' group. On the BSE, 56599 shares were traded on the counter so far as against the average daily volumes of 2500 shares in the past one month. Anmol India Ltd soared 17.95% to Rs 13.34. The stock was the third biggest gainer in 'B' group. On the BSE, 1.97 lakh shares were traded on the counter so far as against the average daily volumes of 9117 shares in the past one month. Medi Caps Ltd gained 17.41% to Rs 31.7. The stock was the fourth biggest gainer in 'B' group. On the BSE, 26182 shares were traded on the counter so far as against the average daily volumes of 1661 shares in the past one month. Goa Carbon Ltd rose 16.74% to Rs 452.55. The stock was the fifth biggest gainer in 'B' group. On the BSE, 1.48 lakh shares were traded on the counter so far as against the average daily volumes of 850 shares in the past one month.

Novartis India Limited announced that its Board of Directors approved the adoption of a new Memorandum of Association to align with the Companies Act, 2013, and a proposal to change the company’s name, both subject to shareholder approval at the upcoming Annual General Meeting. The decisions were made at a board meeting held on Monday, August 17, 2026, and also included an amendment to the Notice of the 78th Annual General Meeting previously approved on August 7, 2026.

Novartis India Limited informed the BSE Limited that its board approved the termination of a distribution and promotion agreement with Dr. Reddy’s Laboratories Limited, dated February 11, 2022, with an effective termination date of September 30, 2026, to re-acquire exclusivity and secure market access for certain products.